<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Prospective Grant of An Exclusive Evaluation Option License: Pre-clinical Evaluation of Anti-tyrosine Kinase-like Orphan Receptor 1 Immunotoxins for the Treatment of Human Cancers</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Prospective Grant of An Exclusive Evaluation Option License: Pre-clinical Evaluation of Anti-tyrosine Kinase-like Orphan Receptor 1 Immunotoxins for the Treatment of Human Cancers</h1>
    <p class="timestamp">Published: 2013-04-09 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Patent Application 61/172,099 entitled "Anti-human ROR1 Antibodies" [HHS Ref. E-097-2009/0-US-01], U.S. Patent Application 60/703,798 entitled "Mutated Pseudomonas Exotoxins with Reduced Antigenicity" [HHS Ref. E-262-2005/0-US-01], U.S. Paten...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, National Institutes of Health</p>
    <p><strong>Document Number:</strong> 2013-08148</p>
    <p><strong>Publication Date:</strong> 2013-04-09</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2013/04/09/2013-08148/prospective-grant-of-an-exclusive-evaluation-option-license-pre-clinical-evaluation-of-anti-tyrosine">https://www.federalregister.gov/documents/2013/04/09/2013-08148/prospective-grant-of-an-exclusive-evaluation-option-license-pre-clinical-evaluation-of-anti-tyrosine</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2013-08148</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
